chemical

AT 1

6356

5 mg

374 USD

6356

6356/5

AT 1

(+)-JQ1 based PROTAC with selectivity for BRD4

Active Degraders

Small Molecules

5 mg

98%

972.68

?utm_source=distributor&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

Cell penetrant Proteolysis Targeting Chimera (PROTAC ) compound based on (+)-JQ1 (Cat.No. 4499) conjugated to a von Hippel-Lindau (VHL) ligand. Rationally designed based on a ternary complex crystal structure to improve selectivity for BRD4 degradation compared to MZ1 (Cat.No. 6154). Demonstrates profound and selective degradation of BRD4 in cells at 1-3 M, with negligible loss of BRD2 and BRD3. . PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

6356

PROTAC Proteolysis targeted chimeras Bromodomain BRD2 BRD3 BRD4 BET proteins JQ1 VHL E3 ubiquitin ligase AT1 PROTACs active degraders degrades targeted protein degradation tpd Ubiquitin E3 Ligases Active Degraders Bromodomains 6356, target protein knockdown, PROTAC, SNIPER

(+)-JQ1 based PROTAC with selectivity for BRD4

(2S,4R)-1-(2R)-2-Acetamido-3-[[6-[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetamido]hexyl]thio]-3-methylbutanoyl]-4-hydroxy-N-[4-(4-methylthiazol-5-yl)benzyl)pyrrolidinine-2-carboxamide

C 48 H 58 ClN 9 O 5 S 3

C48H58ClN9O5S3

2098836-45-2

359

374 USD

Store at -20°C